The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research
Open accessAbstract
BACKGROUND: OVARIAN CARCINOMAS CONSIST OF AT LEAST FIVE DISTINCT DISEASES: high-grade serous, low-grade serous, clear cell, endometrioid, and mucinous. Biomarker and molecular characterization may represent a more biologically relevant basis for grouping and treating this family of tumors, rather than site of origin. Molecular characteristics have become the new standard for clinical pathology, however development of tailored type-specific therapies is hampered by a failure of basic research to recognize that model systems used to study these diseases must also be stratified. Unrelated model systems do offer value for study of biochemical processes but specific cellular context needs to be applied to assess relevant therapeutic strategies. METHODS: We have focused on the identification of clear cell carcinoma cell line models. A panel of 32 "ovarian cancer" cell lines has been classified into histotypes using a combination of mutation profiles, IHC mutation-surrogates, and a validated immunohistochemical model. All cell lines were identity verified using STR analysis. RESULTS: Many described ovarian clear cell lines have characteristic mutations (including ARID1A and PIK3CA) and an overall molecular/immuno-profile typical of primary tumors. Mutations in TP53 were present in the majority of high-grade serous cell lines. Advanced genomic analysis of bona-fide clear cell carcinoma cell lines also support copy number changes in typical biomarkers such at MET and HNF1B and a lack of any recurrent expressed re-arrangements. CONCLUSIONS: As with primary ovarian tumors, mutation status of cancer genes like ARID1A and TP53 and a general immuno-profile serve well for establishing histotype of ovarian cancer cell We describe specific biomarkers and molecular features to re-classify generic "ovarian carcinoma" cell lines into type specific categories. Our data supports the use of prototype clear cell lines, such as TOV21G and JHOC-5, and questions the use of SKOV3 and A2780 as models of high-grade serous carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · cited 7×
“Further, loss of ARID1A expression, demonstrated by IHC, showed good concordance with presence of known truncating mutations, as noted for primary tumor specimens [16].”
BackgroundMethodSelf-citationNovel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050232 · Cited by 814
Self-citationDriver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 680
Vang, R., Shih, I.-M., & Kurman, R. J. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181b4fffa · Cited by 562
deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data
McPherson, A., Hormozdiari, F., Zayed, A., Giuliany, R., Ha, G., Sun, M. G. F., Griffith, M., Heravi Moussavi, A., Senz, J., Melnyk, N., et al. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001138 · Cited by 557 · cited 1×
“Expressed re-arrangements were predicted from transcriptome sequencing data for CCC cell lines TOV21G, JHOC-5, JHOC-7, JHOC-9, and RMG-2 using deFuse [40] (Table S3).”
MethodSelf-citationCheck your cultures! A list of cross‐contaminated or misidentified cell lines
Capes‐Davis, A., Theodosopoulos, G., Atkin, I., Drexler, H. G., Kohara, A., MacLeod, R. A. F., Masters, J. R., Nakamura, Y., Reid, Y. A., Reddel, R. R., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25242 · Cited by 520 · cited 1×
“Additionally, human error, mislabeling and the generic feature of ‘‘epithelial-like’’ cell lines have also led to mix ups of cell lines and contamination which has resulted in un-interpretable data [32,33].”
BackgroundMcCluggage, W. G. (2011) · Pathology · doi:10.1097/pat.0b013e328348a6e7 · Cited by 497
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081000 · Cited by 485
Farley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70572-7 · Cited by 413
Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas
Köbel, M., Kalloger, S. E., Huntsman, D. G., Santos, J. L., Swenerton, K. D., Seidman, J. D., & Gilks, C. B. (2010) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181c042b6 · Cited by 398
Self-citationPrecursor lesions of ovarian epithelial malignancy
Feeley, K. M., & Wells, M. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01042.x · Cited by 351
Lessons from BRCA: the Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer
Crum, C. P., Drapkin, R., Kindelberger, D., Medeiros, F., Miron, A., & Lee, Y. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.702 · Cited by 342
Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment
Hess, V., A'Hern, R., Nasiri, N., King, D. M., Blake, P. R., Barton, D. P. J., Shepherd, J. H., Ind, T., Bridges, J., Harrington, K., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.078 · Cited by 333
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene
Zhang, X., George, J., Deb, S., Degoutin, J. L., Takano, E. A., Fox, S. B., AOCS Study group, Bowtell, D. D. L., & Harvey, K. F. (2011) · Oncogene · doi:10.1038/onc.2011.8 · Cited by 309
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L. M., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301
Self-citationShaw, T. J., Senterman, M. K., Dawson, K., Crane, C. A., & Vanderhyden, B. C. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.013 · Cited by 278
Anglesio, M. S., Carey, M. S., Köbel, M., MacKay, H., & Huntsman, D. G. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.005 · Cited by 272
Self-citationMackay, H. J., Brady, M. F., Oza, A. M., Reuss, A., Pujade-Lauraine, E., Swart, A. M., Siddiqui, N., Colombo, N., Bookman, M. A., Pfisterer, J., et al. (2010) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181dd0110 · Cited by 271
Ovarian cancer incidence in the United States, 1992–1999
Quirk, J. T., & Natarajan, N. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.02.007 · Cited by 268
Histologic Subtypes of Ovarian Carcinoma: An Overview
Soslow, R. A. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31815ea812 · Cited by 258
Anglesio, M. S., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P. A., House, C. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3314 · Cited by 258
Self-citationKorch, C., Spillman, M. A., Jackson, T. A., Jacobsen, B. M., Murphy, S. K., Lessey, B. A., Jordan, V. C., & Bradford, A. P. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.017 · Cited by 251
Self-citationNeoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Schmeler, K. M., Sun, C. C., Bodurka, D. C., T. Deavers, M., Malpica, A., Coleman, R. L., Ramirez, P. T., & Gershenson, D. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.013 · Cited by 245
Gilks, C. B., Ionescu, D. N., Kalloger, S. E., Köbel, M., Irving, J., Clarke, B., Santos, J., Le, N., Moravan, V., & Swenerton, K. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.01.003 · Cited by 242
Self-citationKöbel, M., Kalloger, S. E., Carrick, J., Huntsman, D., Asad, H., Oliva, E., Ewanowich, C. A., Soslow, R. A., & Gilks, C. B. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181788546 · Cited by 231
Self-citationMcAlpine, J. N., Wiegand, K. C., Vang, R., Ronnett, B. M., Adamiak, A., Köbel, M., Kalloger, S. E., Swenerton, K. D., Huntsman, D. G., Gilks, C. B., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-433 · Cited by 215
Self-citationLevanon, K., Ng, V, Piao, H. Y., Zhang, Y., Chang, M. C., Roh, M. H., Kindelberger, D. W., Hirsch, M. S., Crum, C. P., Marto, J. A., et al. (2010) · Oncogene · doi:10.1038/onc.2009.402 · Cited by 214
Anglesio, M. S., Kommoss, S., Tolcher, M. C., Clarke, B., Galletta, L., Porter, H., Damaraju, S., Fereday, S., Winterhoff, B. J., Kalloger, S. E., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4088 · Cited by 198
Self-citationOvarian tumors associated with atypical endometriosis
LaGrenade, A., & Silverberg, S. G. (1988) · Human Pathology · doi:10.1016/s0046-8177(88)80090-x · Cited by 195
McAlpine, J. N., Porter, H., Köbel, M., Nelson, B. H., Prentice, L. M., Kalloger, S. E., Senz, J., Milne, K., Ding, J., Shah, S. P., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.211 · Cited by 185
Self-citationEndometriosis and Ovarian Cancer: A Review of Clinical, Pathologic, and Molecular Aspects
Wei, J.-J., William, J., & Bulun, S. (2011) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31821f4b85 · Cited by 174
The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas
Köbel, M., Reuss, A., Bois, A. D., Kommoss, S., Kommoss, F., Gao, D., Kalloger, S. E., Huntsman, D. G., & Gilks, C. B. (2010) · The Journal of Pathology · doi:10.1002/path.2744 · Cited by 170
Self-citationThe Changing View of High-Grade Serous Ovarian Cancer
Berns, E. M. J. J., & Bowtell, D. D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3911 · Cited by 169
Seidman, J. D., & Khedmati, F. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/132.11.1753 · Cited by 168
Hirasawa, A., Saito-Ohara, F., Inoue, J., Aoki, D., Susumu, N., Yokoyama, A., Nozawa, S., Inazawa, J., & Imoto, I. (2003) · PubMed · Cited by 166
Intercepting pelvic cancer in the distal fallopian tube: Theories and realities
Crum, C. P. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.01.004 · Cited by 166
PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas
Tan, D. S. P., Lambros, M. B. K., Rayter, S., Natrajan, R., Vatcheva, R., Gao, Q., Marchiò, C., Geyer, F. C., Savage, K., Parry, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2403 · Cited by 164
Molecular genetic evidence that endometriosis is a precursor of ovarian cancer
Prowse, A. H., Manek, S., Varma, R., Liu, J., Godwin, A. K., Maher, E. R., Tomlinson, I. P. M., & Kennedy, S. H. (2006) · International Journal of Cancer · doi:10.1002/ijc.21845 · Cited by 164
Malkov, V. A., Serikawa, K. A., Balantac, N., Watters, J., Geiss, G., Mashadi-Hossein, A., & Fare, T. (2009) · BMC Research Notes · doi:10.1186/1756-0500-2-80 · Cited by 161
Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible: A Transcanadian Study
Köbel, M., Kalloger, S. E., Baker, P. M., Ewanowich, C. A., Arseneau, J., Zherebitskiy, V. A., Abdulkarim, S., Leung, S. C. Y., Duggan, M. A., Fontaine, D., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181e1a3bb · Cited by 156
Self-citationCell-mediated immunity to human malignant cells
DiSaia, P. J., Sinkovics, J. G., Rutledge, F. N., & Smith, J. P. (1972) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(72)90109-3 · Cited by 153
The Origin of Ovarian Carcinomas: A Unifying Hypothesis
Auersperg, N. (2010) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181f45f3e · Cited by 150
Survival among U.S. Women with Invasive Epithelial Ovarian Cancer
McGuire, V. M., Jesser, C. A., & Whittemore, A. S. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2001.6536 · Cited by 146
Cai, K. Q. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.12.009 · Cited by 144
Anglesio, M. S., Arnold, J. M., George, J., Tinker, A. V., Tothill, R. W., Waddell, N., Simms, L. A., Locandro, B., Fereday, S., Traficante, N., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0193 · Cited by 144
Self-citationGenomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas
Tan, D. S. P., Iravani, M., McCluggage, W. G., Lambros, M. B. K., Milanezi, F., Mackay, A. G., Gourley, C., Geyer, F. C., Vatcheva, R., Millar, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1688 · Cited by 142
Köbel, M., Kalloger, S. E., Santos, J. L., Huntsman, D. D., Gilks, C. B., & Swenerton, K. D. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.029 · Cited by 133
Self-citationDuska, L., Garrett, L. A., Henretta, M. S., Ferriss, J. S., Lee, L. K., & Horowitz, N. S. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.10.069 · Cited by 127
Histopathologic Features of Genetically Determined Ovarian Cancer
Shaw, P. A., McLaughlin, J. R., Zweemer, R. P., Narod, S. A., Risch, H. A., Verheijen, R. H. M., Ryan, A., Menko, F. H., Kenemans, P., & Jacobs, I. J. (2002) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200210000-00011 · Cited by 120
Jensen, K. C., Mariappan, M. R., Putcha, G. V., Husain, A., Chun, N., Ford, J. M., Schrijver, I., & Longacre, T. A. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31816380c4 · Cited by 113
Calculator for ovarian carcinoma subtype prediction
Kalloger, S. E., Köbel, M., Leung, S. C. Y., Mehl, E., Gao, D., Marcon, K. M., Chow, C., Clarke, B. A., Huntsman, D. D., & Gilks, C. B. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.215 · Cited by 111
Self-citationMadore, J., Ren, F., Filali‐Mouhim, A., Sanchez, L. M., Köbel, M., Tonin, P. N., Huntsman, D. D., Provencher, D. M., & Mes‐Masson, A. (2009) · The Journal of Pathology · doi:10.1002/path.2659 · Cited by 110
Self-citationDNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma
Kuo, K., Mao, T., Chen, X., Feng, Y., Nakayama, K., Wang, Y., Glas, R., Ma, M. J., Kurman, R. J., Shih, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2105 · Cited by 107
Endometrioid epithelial ovarian cancer
Storey, D. J., Rush, R., Stewart, M., Rye, T., Al-Nafussi, A., Williams, A. R. W., Smyth, J. F., & Gabra, H. (2008) · Cancer · doi:10.1002/cncr.23438 · Cited by 102
Molecular Genetic Defects in Endometriosis
Thomas, E. J., & Campbell, I. (2000) · Gynecologic and Obstetric Investigation · doi:10.1159/000052878 · Cited by 102
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes
McBride, D. J., Etemadmoghadam, D., Cooke, S. L., Alsop, K., George, J., Butler, A. P., Cho, J., Galappaththige, D., Greenman, C., Howarth, K., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4042 · Cited by 102
Yamamoto, S., Tsuda, H., Miyai, K., Takano, M., Tamai, S., & Matsubara, O. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.70 · Cited by 90
Evidence that Endometriosis Behaves in a Malignant Manner
Thomas, E. J., & Campbell, I. (2000) · Gynecologic and Obstetric Investigation · doi:10.1159/000052872 · Cited by 87
Taverna, P., Liu, L., Hanson, A. J., Monks, A. P., & Gerson, S. L. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000186 · Cited by 87
Rahman, M. T., Nakayama, K., Rahman, M., Nakayama, N., Ishikawa, M., Katagiri, A., Iida, K., Nakayama, S., Otsuki, Y., Shih, I., et al. (2011) · Cancer · doi:10.1002/cncr.26598 · Cited by 77
Lu, F., Gilks, C. B., Mulligan, A. M., Ryan, P. M., Allo, G., Sy, K., Shaw, P. A., Pollett, A. F., & Clarke, B. A. (2012) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31824fe2aa · Cited by 74
Endometriosis: candidate genes
Campbell, I., & Thomas, E. J. (2001) · Human Reproduction Update · doi:10.1093/humupd/7.1.15 · Cited by 74
Altman, A. D., Nelson, G. S., Ghatage, P., McIntyre, J. B., Capper, D., Chu, P., Nation, J. G., Karnezis, A. N., Han, G., Kalloger, S. E., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.55 · Cited by 71
Self-citationCramer, S. F., Roth, L. M., Ulbright, T. M., et al. (1987) · PubMed · Cited by 70
Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers
Swenerton, K. D., Santos, J. L., Gilks, C. B., Köbel, M., Hoskins, P. J., Wong, F., & Le, N. D. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq383 · Cited by 66
Spowart, J. E., Townsend, K. N., Huwait, H., Eshragh, S., West, N. R., Ries, J., Kalloger, S. E., Anglesio, M. S., Gorski, S. M., Watson, P. H., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4090 · Cited by 62
Self-citationWarnick, C. T., Dabbas, B., Ford, C. D., & Strait, K. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103088200 · Cited by 61
Treatment of Ovarian Cancer in Young Women
Gershenson, D. M. (2012) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e318248045b · Cited by 59
Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer
Liu, J., Albarracin, C. T., Chang, K., Thompson-Lanza, J. A., Zheng, W., Gershenson, D. M., Broaddus, R. R., & Luthra, R. (2003) · Modern Pathology · doi:10.1038/modpathol.3800017 · Cited by 58
Domanska, K., Malander, S., Måsbäck, A., & Nilbert, M. C. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00875.x · Cited by 48
Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?
Hunter, S. M., Anglesio, M. S., Sharma, R. N., Gilks, C. B., Melnyk, N., Chiew, Y.-E., DeFazio, A., Longacre, T. A., Huntsman, D. D., Gorringe, K. L., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2080 · Cited by 38
Self-citationMixed Clear Cell and Endometrioid Carcinoma Arising in Parietal Endometriosis
Razzouk, K., Roman, H., Chanavaz‐Lacheray, I., Scotté, M., Verspyck, É., & Marpeau, L. (2006) · Gynecologic and Obstetric Investigation · doi:10.1159/000096437 · Cited by 36
Yamamoto, S., Tsuda, H., Miyai, K., Takano, M., Tamai, S., & Matsubara, O. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.143 · Cited by 32
Danjoh, I., Shirota, R., Hiroyama, T., & Nakamura, Y. (2012) · Cytogenetic and Genome Research · doi:10.1159/000343757 · Cited by 6
Research works printed but not linked: 8
- JW Carlson, 2010, Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications, Int J Gynecol Pathol, 29, 310, 10.1097/PGP.0b013e3181c713a8 · doi:10.1097/pgp.0b013e3181c713a8
- AR Laury, 2011, Fallopian tube correlates of ovarian serous borderline tumors, Am J Surg Pathol, 35, 1759, 10.1097/PAS.0b013e318233b0f7 · doi:10.1097/pas.0b013e318233b0f7
- Schiavone MB, Herzog TJ, Lewin SN, Deutsch I, Sun X, <etal>et al</etal>.. (2011) Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol 205: 480 e481–488. · doi:10.1016/j.ajog.2011.06.049
- Kommoss S, Gilks CB, Kommoss F, Anglesio MS, Chow C, <etal>et al</etal>.. (2013) Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. Histopathology (accepted June 2, 2013). · DOI
- M Kobel, 2011, Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites, Int J Gynecol Pathol, 30, 366, 10.1097/PGP.0b013e31820d20ba · DOI
- Farley JH, Brady WE, Birrer MJ, Lankes H, Coleman R, <etal>et al</etal>.. (2012) A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. AACR Annual Meeting 2012, Chicogo, IL, USA. · doi:10.1158/1538-7445.am2012-ct-05
- E Hernandez, 1984, Interobserver variability in the interpretation of epithelial ovarian cancer, Gynecol Oncol, 17, 117, 10.1016/0090-8258(84)90065-9 · doi:10.1016/0090-8258(84)90065-9
- A Sakamoto, 1994, Observer disagreement in histological classification of ovarian tumors in Japan, Gynecol Oncol, 54, 54, 10.1006/gyno.1994.1165 · doi:10.1006/gyno.1994.1165
Cited by
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Self-citationLabel-free detection and molecular profiling of exosomes with a nano-plasmonic sensor
Im, H., Shao, H., Park, Y. I., Peterson, V. M., Castro, C. M., Weissleder, R., & Lee, H. (2014) · Nature Biotechnology · doi:10.1038/nbt.2886 · Cited by 1,321
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., Schultz, D. C., Liu, Q., Shih, I.-M., Conejo-Garcia, J. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3799 · Cited by 678
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
“Comparison of our results with the two earlier studies [31,57] shows similar prediction for HGS and some discrepancies for the non-serous cell lines.”
MethodResult
Metadata
- Authors
- Anglesio, M. S., Wiegand, K. C., Melnyk, N., Chow, C., Salamanca, C., Prentice, L. M., Senz, J., Yang, W., Spillman, M. A., Cochrane, D. R., Shumansky, K., Shah, S. P., Kalloger, S. E., & Huntsman, D. G.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-09-04
- Volume
- 8
- Issue
- 9
- Pages
- e72162
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2025669441
- Cited by
- 253
- References
- 85
- FWCI
- 23.70
- Type
- journal article
- Language
- en
- Update notices
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.